Title : The strategy that works on patients, not just in experiments
Abstract:
Randomized Controlled Trials (RCT) have been the gold standard for measuring the effects of health-care services for 50 years. However, RCTs do neither describe real-word effectiveness (RWE) nor added value of these ser-vices for patients, but only the theoretical proof of principle (POP) under experimental conditions. Over the past 30 years, our group has developed a method that can be used to measure the RWE of healthcare services that reaches the patient. This method is essential for all decision makers in ethics, epidemiology, healthcare, health economy, law, and politics. The lecture describes (1) the three conditions of care (the experimental study condition in RCTs, the pragmatic study conditions in pragmatic controlled trials (PCTs), and the non-experimental Care as Usual (CAU). (2) the functional and 13 structural elements that are different in the three conditions of care, (3) the difference of experimental and pragmatic studies with or without systematic analysis of outcomes, and finally (4) a summary of added value to all parts of society.
Biography:
Franz Porzsolt attended Medical School at Philipps University of Marburg, Germany, from 1967 to 1974. He then became a grantee of the German Research Association (DFG) at the Ontario Cancer Institute in Toronto from 1974 to 1976. Between 1976 and 1984, he served as a resident in Hematology and Medical Oncology and completed his habilitation at the University of Ulm. From 1985 to 1993, he worked as a senior resident and supervisor in Hematology/Medical Oncology, and from 1993 to 1995, he served as managing supervisor of the Department of Internal Medicine at the University Hospital Ulm. Concurrently, from 1985 to 1996, he held the role of Scientific Secretary for the Comprehensive Cancer Center at the University Hospital Ulm. In 1995, he joined the Cochrane Cooperation’s working group “Clinical Economics.” His career included international academic engagements, such as serving as a Visiting Professor at the Mayo Clinic in 2005 and acting as a reviewer for the International Atomic Energy Agency (IAEA) in 2009. From 2009 to 2018, he was also a Visiting Professor at several Brazilian universities, including UFF, USP & UNIFESP, UNILA & UNIOESTE, and the Escola Bahiana de Medicina. In 2013, he founded a private research institute, Clinical Economics.
